# Therachon

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/therachon

- Industry: Biotechnology
- Headquarters: Basel, Switzerland
- Website: www.therachon.com
- Total disclosed funding: $43M
- Latest round: Series A (Jan 6, 2017)
- Investors on record: 5

## About

Therachon AG is a biopharmaceutical company focused on developing innovative therapies for serious medical conditions, particularly in the field of rare diseases and biologics.Founded in 2014 in Basel, Switzerland, Therachon AG specializes in biopharmaceuticals targeting rare diseases. The company was acquired by Pfizer Inc. in May 2019 for USD 340.00 mn, with total funding raised amounting to USD 340.00 mn. The acquisition included an additional USD 470.00 mn contingent upon achieving development and commercialization milestones.Therachon AG's product offerings focus on biopharmaceuticals designed to treat rare diseases. Their innovative therapies aim to address significant health challenges through advanced biologic treatments and targeted drug combinations, ensuring effective solutions for patients globally.Therachon AG generates revenue through partnerships with healthcare systems and direct sales of its therapies. Their revenue model includes B2B transactions with hospitals, clinics, and retail pharmacies, often structured around negotiated contracts that may vary based on service volume.In the years following its acquisition, Therachon AG intends to leverage Pfizer's extensive resources to expedite the development of upcoming therapies and expand its market presence. The recent acquisition funding will support the launch of new products targeting rare diseases and bolster the company’s expansion into additional therapeutic areas, aiming for broader geographical reach in North America and Europe by 2022.

## Funding rounds

- Series A, Jan 6, 2017, $5M — OrbiMed Advisors, Versant Ventures, Inserm Transfert Initiative, Bpifrance Investissement
- Series A, Sep 30, 2015, $35M — New Enterprise Associates, OrbiMed Advisors, Versant Ventures, Inserm Transfert Initiative
- Seed, Jul 1, 2014, $2.7M — Versant Ventures, Inserm Transfert Initiative

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Seed, Series A
- Inserm Transfert Initiative (https://capitalatlas.ai/funds/inserm-transfert-initiative) — Seed, Series A
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A